|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Williet N, Fovet M and Phelip JM:
Management of metastatic colorectal cancer. Rev Prat. 65:793–797.
2015.(In French). PubMed/NCBI
|
|
3
|
Ciombor KK, Wu C and Goldberg RM: Recent
therapeutic advances in the treatment of colorectal cancer. Annu
Rev Med. 66:83–95. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kibe S, Yutani S, Motoyama S, Nomura T,
Tanaka N, Kawahara A, Yamaguchi T, Matsueda S, Komatsu N, Miura M,
et al: Phase II study of personalized peptide vaccination for
previously treated advanced colorectal cancer. Cancer Immunol Res.
2:1154–1162. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hunyadi J, András C, Szabó I, Szántó J,
Szluha K, Sipka S, Kovács P, Kiss A, Szegedi G, Altorjay I, et al:
Autologous dendritic cell based adoptive immunotherapy of patients
with colorectal cancer-A phase I–II study. Pathol Oncol Res.
20:357–365. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Diaz LA Jr and Le DT: PD-1 Blockade in
tumors with mismatch-repair deficiency. N Engl J Med. 373:19792015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Copier J, Whelan M and Dalgleish A:
Biomarkers for the development of cancer vaccines: current status.
Mol Diagn Ther. 10:337–343. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Whiteside TL: Immune responses to cancer:
Are they potential biomarkers of prognosis? Front Oncol. 3:1072013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lagos-Quintana M, Rauhut R, Lendeckel W
and Tuschl T: Identification of novel genes coding for small
expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee RC and Ambros V: An extensive class of
small RNAs in Caenorhabditis elegans. Science. 294:862–864. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Facciabene A, Motz GT and Coukos G:
T-regulatory cells: key players in tumor immune escape and
angiogenesis. Cancer Res. 72:2162–2171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ueda R, Kohanbash G, Sasaki K, Fujita M,
Zhu X, Kastenhuber ER, McDonald HA, Potter DM, Hamilton RL, Lotze
MT, et al: Dicer-regulated microRNAs 222 and 339 promote resistance
of cancer cells to cytotoxic T-lymphocytes by down-regulation of
ICAM-1. Proc Natl Acad Sci USA. 106:10746–10751. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sonda N, Simonato F, Peranzoni E, Calì B,
Bortoluzzi S, Bisognin A, Wang E, Marincola FM, Naldini L, Gentner
B, et al: miR-142-3p prevents macrophage differentiation during
cancer-induced myelopoiesis. Immunity. 38:1236–1249. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Trifari S, Pipkin ME, Bandukwala HS, Äijö
T, Bassein J, Chen R, Martinez GJ and Rao A: MicroRNA-directed
program of cytotoxic CD8+ T-cell differentiation. Proc
Natl Acad Sci USA. 110:18608–18613. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Min D, Lv XB, Wang X, Zhang B, Meng W, Yu
F and Hu H: Downregulation of miR-302c and miR-520c by
1,25(OH)2D3 treatment enhances the
susceptibility of tumour cells to natural killer cell-mediated
cytotoxicity. Br J Cancer. 109:723–730. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang Z, Huang D, Ni S, Peng Z, Sheng W
and Du X: Plasma microRNAs are promising novel biomarkers for early
detection of colorectal cancer. Int J Cancer. 127:118–126. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yuan D, Li K, Zhu K, Yan R and Dang C:
Plasma miR-183 predicts recurrence and prognosis in patients with
colorectal cancer. Cancer Biol Ther. 16:268–275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hazama S, Nakamura Y, Takenouchi H, Suzuki
N, Tsunedomi R, Inoue Y, Tokuhisa Y, Iizuka N, Yoshino S, Takeda K,
et al: A phase I study of combination vaccine treatment of five
therapeutic epitope-peptides for metastatic colorectal cancer;
safety, immunological response, and clinical outcome. J Transl Med.
12:632014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hazama S, Nakamura Y, Tanaka H, Hirakawa
K, Tahara K, Shimizu R, Ozasa H, Etoh R, Sugiura F, Okuno K, et al:
A phase II study of five peptides combination with
oxaliplatin-based chemotherapy as a first-line therapy for advanced
colorectal cancer (FXV study). J Transl Med. 12:1082014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hazama S, Takenouchi H, Tsunedomi R, Iida
M, Suzuki N, Iizuka N, Inoue Y, Sakamoto K, Nakao M, Shindo Y, et
al: Predictive biomarkers for the outcome of vaccination of five
therapeutic epitope peptides for colorectal cancer. Anticancer Res.
34:4201–4205. 2014.PubMed/NCBI
|
|
21
|
Shindo Y, Hazama S, Nakamura Y, Inoue Y,
Kanekiyo S, Suzuki N, Takenouchi H, Tsunedomi R, Nakajima M, Ueno
T, et al: miR-196b, miR-378a and miR-486 are predictive biomarkers
for the efficacy of vaccine treatment in colorectal cancer. Oncol
Lett. (In Press).
|
|
22
|
Uchida N, Tsunoda T, Wada S, Furukawa Y,
Nakamura Y and Tahara H: Ring finger protein 43 as a new target for
cancer immunotherapy. Clin Cancer Res. 10:8577–8586. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shimokawa T, Matsushima S, Tsunoda T,
Tahara H, Nakamura Y and Furukawa Y: Identification of TOMM34,
which shows elevated expression in the majority of human colon
cancers, as a novel drug target. Int J Oncol. 29:381–386.
2006.PubMed/NCBI
|
|
24
|
Suda T, Tsunoda T, Daigo Y, Nakamura Y and
Tahara H: Identification of human leukocyte antigen-A24-restricted
epitope peptides derived from gene products upregulated in lung and
esophageal cancers as novel targets for immunotherapy. Cancer Sci.
98:1803–1808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ishizaki H, Tsunoda T, Wada S, Yamauchi M,
Shibuya M and Tahara H: Inhibition of tumor growth with
antiangiogenic cancer vaccine using epitope peptides derived from
human vascular endothelial growth factor receptor 1. Clin Cancer
Res. 12:5841–5849. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wada S, Tsunoda T, Baba T, Primus FJ,
Kuwano H, Shibuya M and Tahara H: Rationale for antiangiogenic
cancer therapy with vaccination using epitope peptides derived from
human vascular endothelial growth factor receptor 2. Cancer Res.
65:4939–4946. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Smyth GK: limma: Linear models for
microarray dataBioinformatics and Computational Biology Solutions
Using R and Bioconductor: Statistics for Biology and Health.
Gentleman R, Carey V, Dudoit S, Irizarry R and Huber W: Springer;
New York: pp. 397–420. 2005, View Article : Google Scholar
|
|
28
|
Hu Z, Dong J, Wang LE, Ma H, Liu J, Zhao
Y, Tang J, Chen X, Dai J, Wei Q, et al: Serum microRNA profiling
and breast cancer risk: the use of miR-484/191 as endogenous
controls. Carcinogenesis. 33:828–834. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zheng G, Wang H, Zhang X, Yang Y, Wang L,
Du L, Li W, Li J, Qu A, Liu Y, et al: Identification and validation
of reference genes for qPCR detection of serum microRNAs in
colorectal adenocarcinoma patients. PLoS One. 8:e830252013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Boon T and van der Bruggen P: Human tumor
antigens recognized by T lymphocytes. J Exp Med. 183:725–729. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kojima M, Sudo H, Kawauchi J, Takizawa S,
Kondou S, Nobumasa H and Ochiai A: MicroRNA markers for the
diagnosis of pancreatic and biliary-tract cancers. PLoS One.
10:e01182202015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shimomura A, Shiino S, Kawauchi J,
Takizawa S, Sakamoto H, Matsuzaki J, Ono M, Takeshita F, Niida S,
Shimizu C, et al: Novel combination of serum microRNA for detecting
breast cancer in the early stage. Cancer Sci. 107:326–334. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen S, Wang L, Fan J, Ye C, Dominguez D,
Zhang Y, Curiel TJ, Fang D, Kuzel TM and Zhang B: Host miR155
promotes tumor growth through a myeloid-derived suppressor
cell-dependent mechanism. Cancer Res. 75:519–531. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zheng Y, Josefowicz SZ, Kas A, Chu TT,
Gavin MA and Rudensky AY: Genome-wide analysis of Foxp3 target
genes in developing and mature regulatory T cells. Nature.
445:936–940. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gajewski TF, Schreiber H and Fu YX: Innate
and adaptive immune cells in the tumor microenvironment. Nat
Immunol. 14:1014–1022. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Okazaki T, Tanaka Y, Nishio R, Mitsuiye T,
Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N, et
al: Autoantibodies against cardiac troponin I are responsible for
dilated cardiomyopathy in PD-1-deficient mice. Nat Med.
9:1477–1483. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
